Illumina (NASDAQ:ILMN) Given New $340.00 Price Target at Argus

Illumina (NASDAQ:ILMN) had its target price lowered by Argus to $340.00 in a report published on Thursday morning, The Fly reports. The brokerage currently has a buy rating on the life sciences company’s stock.

ILMN has been the topic of several other reports. Deutsche Bank increased their price target on Spirit Airlines from $75.00 to $79.00 and gave the company a buy rating in a report on Friday, July 12th. Zacks Investment Research cut GasLog Partners LP Unit from a hold rating to a strong sell rating in a report on Tuesday, April 2nd. BidaskClub cut Weyco Group from a sell rating to a strong sell rating in a report on Saturday, July 13th. Cowen increased their price target on Solaredge Technologies from $65.00 to $74.00 and gave the company an outperform rating in a report on Friday, July 12th. Finally, Bank of America set a $80.00 price target on Colgate-Palmolive and gave the company a buy rating in a report on Friday, July 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company. Illumina presently has an average rating of Buy and a consensus price target of $338.69.

NASDAQ ILMN opened at $293.20 on Thursday. The company’s fifty day moving average price is $342.44. The company has a market cap of $43.10 billion, a PE ratio of 51.26, a price-to-earnings-growth ratio of 2.56 and a beta of 1.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33. Illumina has a 1-year low of $268.62 and a 1-year high of $380.76.



Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.26. The firm had revenue of $846.00 million for the quarter, compared to analysts’ expectations of $838.70 million. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The company’s revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.45 EPS. As a group, analysts expect that Illumina will post 6.34 EPS for the current fiscal year.

In related news, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $302.04, for a total value of $3,020,400.00. Following the transaction, the senior vice president now directly owns 86,776 shares of the company’s stock, valued at approximately $26,209,823.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $376.50, for a total value of $1,242,450.00. Following the completion of the transaction, the director now directly owns 272,616 shares in the company, valued at $102,639,924. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,291 shares of company stock worth $22,479,634. 0.38% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in shares of Illumina by 2.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 256,825 shares of the life sciences company’s stock valued at $77,031,000 after buying an additional 5,007 shares during the period. Geode Capital Management LLC raised its stake in shares of Illumina by 10.1% in the fourth quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock valued at $555,173,000 after buying an additional 170,046 shares during the period. Weiss Multi Strategy Advisers LLC raised its stake in shares of Illumina by 380.0% in the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 6,000 shares of the life sciences company’s stock valued at $1,800,000 after buying an additional 4,750 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Illumina in the fourth quarter valued at $12,959,000. Finally, MML Investors Services LLC raised its stake in shares of Illumina by 4.4% in the fourth quarter. MML Investors Services LLC now owns 2,318 shares of the life sciences company’s stock valued at $695,000 after buying an additional 97 shares during the period. 89.82% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Further Reading: What is a conference call?

The Fly

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.